ESTRACE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ESTRACE (ESTRACE).
Estradiol, a form of estrogen, binds to and activates nuclear estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and subsequent physiological effects including development of secondary sexual characteristics, regulation of reproductive cycle, and effects on bone density, lipid metabolism, and cardiovascular system.
| Metabolism | Primarily hepatic metabolism via cytochrome P450 3A4 isoenzyme to estrone and estriol, which undergo conjugation (glucuronidation and sulfation) and enterohepatic recirculation. Minor metabolism via 2-hydroxylation and 16α-hydroxylation. |
| Excretion | Renal: 50-80% as glucuronide and sulfate conjugates; fecal: 10-20%; biliary: minor (<5%). |
| Half-life | Terminal half-life: 13-27 hours (mean 19 hours); clinical context: supports once-daily dosing for hormone replacement. |
| Protein binding | 98-99% bound to albumin and sex hormone-binding globulin (SHBG). |
| Volume of Distribution | Vd: 1.2 L/kg (range 0.8-1.6 L/kg); clinical meaning: extensive distribution into tissues, including adipose and reproductive organs. |
| Bioavailability | Oral: 2-10% due to extensive first-pass metabolism; intramuscular: 100% (estradiol valerate); intravaginal: 5-20% (cream), 80-100% (ring, systemic absorption). |
| Onset of Action | Oral: 2-4 weeks for full symptomatic relief (hot flashes); intravaginal: 2-4 weeks for vaginal atrophy symptoms; intramuscular: 1-5 minutes (estradiol valerate). |
| Duration of Action | Oral: 24 hours; intravaginal: up to 24 hours (cream) or 3 months (ring); intramuscular: 2-4 weeks (estradiol valerate). |
1 to 2 mg orally once daily for continuous estrogen replacement; 0.1% cream applied vaginally 1 to 2 times daily for atrophic vaginitis.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment necessary for mild to moderate renal impairment; use with caution in severe renal impairment (GFR <30 mL/min) due to potential fluid retention. |
| Liver impairment | Contraindicated in severe hepatic disease (Child-Pugh class C); use with caution in mild to moderate impairment (Child-Pugh class A or B) with dose reduction of 50% and monitoring. |
| Pediatric use | Not indicated for children; for vaginal cream, limited data: 0.5 to 1 g cream vaginally daily for short-term use under specialist guidance. |
| Geriatric use | Initiate at low dose (0.5 mg orally daily or 0.5 g cream vaginally) and titrate slowly; monitor for thromboembolic events and endometrial hyperplasia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ESTRACE (ESTRACE).
| Breastfeeding | Excreted in human milk in small amounts. M/P ratio not established. May reduce milk production and quality. Use while breastfeeding is not recommended. Weigh benefits against potential risks to infant. |
| Teratogenic Risk | Pregnancy category X. Estrogens are contraindicated in pregnancy due to proven fetal harm. First trimester: increased risk of congenital anomalies including cardiovascular and limb defects. Second and third trimesters: fetal toxicity including feminization of male offspring, vaginal adenosis, and cervical anomalies. Uterine growth restriction may occur. |
■ FDA Black Box Warning
Estrogens increase the risk of endometrial cancer in postmenopausal women. Concomitant progestin therapy is recommended in women with an intact uterus. Estrogens should not be used to prevent cardiovascular disease or dementia. The Women's Health Initiative (WHI) substudy reported increased risks of cardiovascular events (e.g., stroke, myocardial infarction), pulmonary embolism, deep vein thrombosis, and probable dementia. The WHI estrogen plus progestin substudy also reported increased risk of invasive breast cancer.
| Serious Effects |
["Undiagnosed abnormal genital bleeding","Known, suspected, or history of breast cancer","Known or suspected estrogen-sensitive neoplasia","Active or history of venous thromboembolism (e.g., DVT, PE)","Active or history of arterial thromboembolism (e.g., stroke, MI)","Known thrombophilic disorders (e.g., protein C, S, or antithrombin deficiency)","Known or suspected pregnancy","Hypersensitivity to estradiol or any component of the formulation","Hepatic impairment or disease"]
| Precautions | ["Cardiovascular disorders: increased risk of stroke, DVT, MI, and pulmonary embolism","Malignancy: endometrial cancer (unopposed estrogen), breast cancer","Dementia: increased risk in women ≥65 years","Gallbladder disease","Hypercalcemia in patients with breast cancer and bone metastases","Visual abnormalities (e.g., retinal vascular thrombosis)","Fluid retention (caution in cardiac or renal impairment)","Hereditary angioedema","Exacerbation of endometriosis","Hypertriglyceridemia (risk of pancreatitis)","Hypothyroidism (may increase thyroid-binding globulin)"] |
Loading safety data…
| Fetal Monitoring |
| Monitor for signs of thrombosis, hypertension, hepatic dysfunction, and glucose intolerance. Fetal monitoring for appropriate growth via ultrasound if exposure occurs. Assess for neonatal adverse effects postpartum. |
| Fertility Effects | May disrupt ovulation and menstrual cycle. Use of exogenous estrogens can inhibit folliculogenesis and implantation. Long-term use may delay return to fertility. No known permanent impairment. |
| Food/Dietary | Grapefruit and grapefruit juice may increase estradiol levels due to CYP3A4 inhibition, but interaction is minimal with transdermal routes. St. John's wort may reduce estradiol efficacy. No specific dietary restrictions; maintain a balanced diet rich in calcium and vitamin D for bone health. |
| Clinical Pearls | Estrace (17β-estradiol) is a bioidentical estrogen used for hormone replacement therapy. Transdermal and topical routes avoid first-pass hepatic metabolism and reduce thromboembolic risk. Use the lowest effective dose for shortest duration. For vaginal atrophy, low-dose vaginal rings or tablets provide local effect with minimal systemic absorption. Contraindicated in breast cancer, active thromboembolic disorders, and undiagnosed abnormal genital bleeding. Assess thrombophilia risk before prescribing. Consider addition of progestin in women with intact uterus to prevent endometrial hyperplasia. |
| Patient Advice | Take exactly as prescribed; do not skip doses or discontinue without consulting your doctor. · Report any vaginal bleeding, breast lumps, chest pain, leg swelling, or shortness of breath immediately. · Do not use during pregnancy or while breastfeeding. · Avoid smoking, as it increases the risk of blood clots and cardiovascular events. · Store at room temperature away from moisture and light. · If you miss a dose, take it as soon as remembered unless almost time for next dose; do not double dose. · Regular gynecologic exams, mammograms, and blood pressure monitoring are recommended. |